Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LipocineLPCN -0.49%46 5-Year Share Buyback Ratio is -6.20 as of Jun. 2026. GuruFocus rates LPCN with a GF Score™ of 46/100 and a GF Value™ of $1.31 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,131 Biotechnology companies, Lipocine ranks better than 62.42% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Lipocine's current 5-Year Share Buyback Ratio was -6.20%.
LPCN's 5-Year Share Buyback Ratio is ranked better than 62.42% of 1131
companies
in the Biotechnology industry
Industry Median: -10.3
vs LPCN: -6.20
Lipocine (NAS:LPCN) 5-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Lipocine 5-Year Share Buyback Ratio Related Terms
LPCN vs NXTC, VYNE, QNCX: 5-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Lipocine's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipocine 5-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipocine's 5-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Lipocine's 5-Year Share Buyback Ratio falls into.
This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Share Buyback Ratio of -6.20 mean?
Lipocine (LPCN) has a 5-Year Share Buyback Ratio of -6.20 as of Jun. 2026. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Lipocine and its competitors. According to the industry distribution chart, Lipocine ranks #425 out of 1131 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Lipocine's 5-Year Share Buyback Ratio too high?
Lipocine's current 5-Year Share Buyback Ratio is -6.20. Based on the distribution chart, Lipocine ranks #425 out of 1131 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lipocine has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lipocine's 5-Year Share Buyback Ratio compare to NXTC and VYNE?
According to the Biotechnology industry distribution chart, Lipocine ranks #425 out of 1131 companies for 5-Year Share Buyback Ratio. This puts Lipocine in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Share Buyback Ratio for a Biotechnology company?
A good 5-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 5-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Share Buyback Ratio mean?
A high 5-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Lipocine and its competitors. Lipocine's current 5-Year Share Buyback Ratio is -6.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Based on GuruFocus' analysis, Lipocine (LPCN) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.31, compared to a current price of $2.05 — trading 56.5% above its estimated fair value. The current 5-Year Share Buyback Ratio is -6.20. Lipocine's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Share Buyback Ratio calculated?
5-Year Share Buyback Ratio is calculated from a company's financial statements. For Lipocine (LPCN), the current 5-Year Share Buyback Ratio is -6.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lipocine (LPCN) Overvalued in 2026?
Based on GuruFocus' analysis, Lipocine stock appears to be overvalued.
The current stock price of $2.05 is trading 56.5% above its estimated GF Value™ of $1.31.
GuruFocus considers Lipocine to be Significantly Overvalued.
Key valuation signals for LPCN:
5-Year Share Buyback Ratio: -6.20
GF Value™: $1.31 vs. price of $2.05 (56.5% above fair value)
No single metric tells the full story. See the LPCN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
46GF Score
Get the complete analysis for LPCN
5-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LPCN has been successfully added to your 
